Latest News for: ccl24

Edit

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in ...

Nasdaq Globe Newswire 18 Jun 2024
New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity ... .
Edit

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease ...

Nasdaq Globe Newswire 18 Apr 2024
Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis ... .
Edit

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

PR Newswire 30 Jan 2024
The new studies reinforce the extensive existing evidence showing that Chemomab's first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes. The study, "The Role of CCL24 in Primary Sclerosing Cholangitis.
Edit

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in ...

The Eagle-Tribune 30 Jan 2024
The new studies reinforce the extensive existing evidence showing that Chemomab's first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes. The study, " The Role of CCL24 in Primary Sclerosing Cholangitis.
Edit

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

PR Newswire 16 Nov 2023
Chemomab's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes ... In this study researchers examined how CCL24 and its receptor, CCR3, might impact EndMT.
Edit

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 ...

The Eagle-Tribune 16 Nov 2023
Chemomab's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes ... In this study researchers examined how CCL24 and its receptor, CCR3, might impact EndMT.
Edit

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

PR Newswire 28 Jun 2023
--Includes Extensive Data Showing that CM-101, Chemomab's CCL24-Neutralizing Antibody,   Interrupts the Fibro-Inflammatory Processes that Lead to PSC-- ... The research article, CCL24 regulates ...
Edit

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

PR Newswire 02 Jun 2023
──New Patient Data Further Implicates CCL24 in Fibrotic Disease Pathology and Prognosis and Supports Rationale for the Role of Chemomab's CCL24-Neutralizing Antibody CM-101in Systemic Sclerosis and Other Fibro-inflammatory Diseases──.
Edit

Chemomab Presents Preclinical Data at AASLD The Liver Meeting® 2022 Highlighting Key Role of CCL24 ...

The Paris News 07 Nov 2022
─New Preclinical Data Further Supports Ability of CCL24-Neutralizing Antibody CM-101 to Interrupt the Pro-inflammatory Immune Cell Migration that Is Key in Primary Sclerosing Cholangitis....
Edit

Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody

PR Newswire 28 Jun 2022
The new patent covers the use of CM-101 and sequence-related CCL24 antibodies for the treatment of hepatic (liver) diseases ... Patent No.11365246, "Anti CCL24 (eotaxin 2) Antibodies for Use in the ...
Edit

Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody (Chemomab Therapeutics Ltd)

Public Technologies 28 Jun 2022
Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody ... The new patent covers the use of CM-101 and sequence-related CCL24 antibodies for the treatment of hepatic (liver) diseases.
Edit

Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022

The Galveston Daily News 02 Jun 2022
—Poster Presentation of Reverse Translational Study Data Using Patient Samples Supports Role of CCL24 as a Therapeutic Target for Systemic Sclerosis— ... dcSSc patients with positive anti-topoisomerase antibodies (ATA) had higher levels of CCL24.

Most Viewed

×